Liposomal daunorubicin
Showing 1 - 25 of 922
Acute Myeloid Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia, Chronic Myelomonocytic Leukemia Trial in Chapel
Recruiting
- Acute Myeloid Leukemia
- +5 more
- Biospecimen Collection
- +3 more
-
Baltimore, Maryland
- +2 more
Jan 19, 2023
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, High Risk
Recruiting
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- +5 more
- Gemtuzumab Ozogamicin
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Sep 22, 2022
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Arising
Not yet recruiting
- Acute Myeloid Leukemia
- +4 more
- Azacitidine
- +6 more
- (no location specified)
Nov 8, 2022
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Tumor, Acute Myeloid
Not yet recruiting
- Acute Myeloid Leukemia
- +3 more
- Azacitidine
- +6 more
- (no location specified)
Nov 15, 2022
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Philadelphia (Palbociclib, Tazemetostat,
Not yet recruiting
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Palbociclib
- +4 more
-
Philadelphia, PennsylvaniaThomas Jefferson University Hospital
Jan 13, 2023
Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial (Azacitidine, Biospecimen Collection, Bone Marrow Aspiration)
Not yet recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
- Azacitidine
- +10 more
- (no location specified)
Jan 13, 2023
Recurrent Acute Myeloid Leukemia Trial in United States (Enasidenib Mesylate, Liposome-encapsulated Daunorubicin-Cytarabine)
Suspended
- Recurrent Acute Myeloid Leukemia
- Enasidenib Mesylate
- Liposome-encapsulated Daunorubicin-Cytarabine
-
Los Angeles, California
- +3 more
Sep 27, 2022
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute
Recruiting
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- +3 more
- Gemtuzumab Ozogamicin
- Liposome-encapsulated Daunorubicin-Cytarabine
-
Houston, TexasM D Anderson Cancer Center
Jun 2, 2021
Acute Lymphocytic Leukemia, Adult Lymphoblastic Lymphoma Trial in United States (DNR, VCR, PEG-asp)
Terminated
- Acute Lymphocytic Leukemia
- Adult Lymphoblastic Lymphoma
- DNR
- +12 more
-
La Jolla, California
- +3 more
Apr 26, 2022
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia
Completed
- Acute Myeloid Leukemia
- +2 more
- Laboratory Biomarker Analysis
- Liposome-encapsulated Daunorubicin-Cytarabine
-
Houston, TexasM D Anderson Cancer Center
Jan 8, 2021
Acute Myeloid Leukaemia Trial in Worldwide (Gemtuzumab ozogamicin, Liposomal daunorubicin, Mitoxantrone)
Recruiting
- Acute Myeloid Leukaemia
- Gemtuzumab ozogamicin
- +6 more
-
Adelaide, Australia
- +67 more
Sep 30, 2021
Acute Myeloid Leukemia Trial in Tianjin ((cytarabine: daunorubicin) liposome for injection, Vyxeos)
Not yet recruiting
- Acute Myeloid Leukemia
- (cytarabine: daunorubicin) liposome for injection
- Vyxeos
-
Tianjin, ChinaInstitute of Hematology and Hospital of Blood Disease, Chinese A
Mar 24, 2023
Acute Myeloid Leukemia Trial in Canada, Puerto Rico, United States (procedure, drug, behavioral)
Recruiting
- Acute Myeloid Leukemia
- Allogeneic Hematopoietic Stem Cell Transplantation
- +13 more
-
Birmingham, Alabama
- +187 more
Apr 28, 2022
Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, Persistent Disease, Refractory Acute Myeloid Leukemia Trial in
Unknown status
- Blasts More Than 5 Percent of Bone Marrow Nucleated Cells
- +2 more
- Liposome-encapsulated Daunorubicin-Cytarabine
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Aug 6, 2019
Acute Myeloid Leukemia With FLT3/ITD Mutation Trial in Tampa (Gilteritinib, Vyxeos)
Suspended
- Acute Myeloid Leukemia With FLT3/ITD Mutation
-
Tampa, FloridaMoffitt Cancer Center
Nov 11, 2022
Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate
Recruiting
- Aggressive Non-Hodgkin Lymphoma
- +8 more
- Polatuzumab Vedotin
- +6 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 26, 2023
Metastatic Kidney Medullary Carcinoma, Metastatic Renal Cell Carcinoma, SMARCB1 Negative Trial in Houston (Doxorubicin,
Recruiting
- Metastatic Kidney Medullary Carcinoma
- +4 more
- Doxorubicin
- +5 more
-
Houston, TexasM D Anderson Cancer Center
Jan 20, 2023
Malignant Abdominal Tumor, Malignant Pelvic Tumor, Recurrent Colon Carcinoma Trial in Rochester (Cisplatin, Cytoreductive
Recruiting
- Malignant Abdominal Neoplasm
- +26 more
- Cisplatin
- +4 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 5, 2023